Unite

Antisense Therapeutics Limited is granted Type C guidance meeting with US FDA for ATL1102 in #DMD to discuss the development of ATL1102 in the US https://www.antisense.com.au//ASX_15-February_ATL1102-FDA-

Parent Project Muscular Dystrophy Invests $1M in Satellos With Goal of Repairing Muscle Cells in Duchenne https://musculardystrophynews.com//ppmd-invests-1m-satell/

Capricor Therapeutics, Inc. Collaborates with Lonza Group for the Development of CAP-1002, its Cell Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy and Other Indications #DMD #Duchenne

Dewpoint Therapeutics Announces Collaboration with Pfizer to Develop Potential Therapies for a Rare Form of #MuscularDystrophy #MyotonicDystrophy #DM1

Pfizer’s Gene Therapy for Duchenne Placed on Fast Track by the FDA

Sarepta Therapeutics announces positive clinical results from MOMENTUM, a Phase 2 Clinical Trial of SRP-5051 in patients with #Duchenne #MuscularDystrophy amenable to skipping Exon 51